Sign In
Buy NMRA
$1.61
+0.0100 (+0.625%)
At Close: Aug 05, 2026
NMRA Stock Earnings: Neumora Therapeutics Meets EPS for Q1 2024
01:54pm, Tuesday, 07'th May 2024
Neumora Therapeutics (NASDAQ: NMRA ) just reported results for the first quarter of 2024. Neumora Therapeutics reported earnings per share of -34 cents.
Neumora Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
07:00am, Tuesday, 07'th May 2024
On-track to report topline Phase 3 data from KOASTAL-1 study with navacaprant in MDD; guidance narrowed to fourth quarter of 2024
Neumora (NMRA) Down on FDA Clinical Hold on Neurology Drug
12:31pm, Tuesday, 16'th Apr 2024
The FDA places a clinical hold on Neumora's (NMRA) phase I study evaluating NMRA-266 for some types of neuropsychiatric disorders. Shares of the company fall on the news.
Why Is Neumora Therapeutics (NMRA) Stock Down 25% Today?
08:45am, Monday, 15'th Apr 2024
Neumora Therapeutics (NASDAQ: NMRA ) stock is falling on Monday after the clinical-stage biopharmaceutical company announced a clinical hold on a Phase 1 trial of NMRA-266. The Food and Drug Administ
Neumora's early-stage schizophrenia drug study put on hold
07:13am, Monday, 15'th Apr 2024
Neumora Therapeutics said on Monday the U.S. Food and Drug Administration (FDA) had placed a clinical hold on early-stage study of its experimental schizophrenia drug, sending its shares down more tha
Neumora Therapeutics Announces Clinical Hold of Phase 1 NMRA-266 Study
06:30am, Monday, 15'th Apr 2024
WATERTOWN, Mass., April 15, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven clinical and
Neumora Therapeutics to Participate at Stifel 2024 Virtual CNS Days
07:00am, Wednesday, 13'th Mar 2024
WATERTOWN, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced tha
Neumora Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
07:00am, Thursday, 07'th Mar 2024
On-track to report topline Phase 3 data from the KOASTAL-1 study with navacaprant in MDD in the second half of 2024 and Phase 1 data with NMRA-266 in healthy adult participants mid-2024
Neumora Therapeutics Appoints Kaya Pai Panandiker as Chief Commercial Officer
07:00am, Monday, 22'nd Jan 2024
WATERTOWN, Mass., Jan. 22, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced the
Why Neumora Therapeutics (NMRA) Stock Might be a Great Pick
09:46am, Wednesday, 10'th Jan 2024
Neumora Therapeutics (NMRA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Neumora Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference
07:00am, Tuesday, 02'nd Jan 2024
WATERTOWN, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced that
7 Stocks with Strong Insider Buying: December 2023
12:35pm, Sunday, 17'th Dec 2023
Many investors are familiar with the idea that there are many reasons why insiders sell shares, but there's only one reason they buy. Insider buying indicates a belief that a company's stock is underv
Neumora Therapeutics Appoints Jason Duncan as Chief Legal Officer
07:00am, Tuesday, 12'th Dec 2023
WATERTOWN, Mass., Dec. 12, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced the
Neumora Therapeutics Announces NMRA-266 IND Clearance and Initiation of Phase 1 Clinical Study
07:00am, Monday, 27'th Nov 2023
NMRA-266 is a highly selective positive allosteric modulator of the M4 muscarinic receptor, a clinically validated target for the treatment of schizophrenia NMRA-266 is a highly selective positive all
IPO pipeline welcomes some profitable companies, raising hopes for a rebound
01:27pm, Monday, 20'th Nov 2023
The U.S. initial public offering calendar is empty this holiday-shortened week, but some recent additions to the pipeline suggest December could be livelier and welcome deals from some profitable, dec
